{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:06:17Z","timestamp":1779782777096,"version":"3.53.1"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Andexanet alfa was recommended by the National Institute for Health and Clinical Excellence (NICE) as an option in the management of life\u2010threatening gastrointestinal bleeding in patients taking apixaban or rivaroxaban in May 2021. A recent UK\u2010wide survey of local hospital protocols for the use of andexanet alfa suggested that practice across the United Kingdom is highly variable. In January 2025, NICE was unable to make a recommendation on the use of andexanet alfa for reversing anticoagulation in adults with intracranial haemorrhage. We set out to report trends and variation in the uptake of andexanet alfa across the NHS in England, using the new OpenPrescribing Hospitals platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To assess the uptake of andexanet alfa, we analysed pharmacy stock control data from NHS trusts in England using the openly available Secondary Care Medicines Dataset. Analysis was restricted to NHS trusts with 24\u2010h consultant\u2010led emergency care activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between May 2021 and June 2025, 19\u2009608 vials of andexanet alfa were issued in NHS trusts in England. There was wide variation in the timing and speed of uptake across NHS trusts. Substantial variation was also observed between NHS Regions in England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of andexanet alfa varies markedly between NHS regions and between NHS trusts in England. This study is the first analysis of adoption of a new treatment using the OpenPrescribing Hospitals platform, which is expected to provide a generalizable framework for similar analyses in the future.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70417","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:10:02Z","timestamp":1766016602000},"page":"1607-1613","source":"Crossref","is-referenced-by-count":1,"title":["Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-3812","authenticated-orcid":false,"given":"Louis","family":"Fisher","sequence":"first","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2738-6236","authenticated-orcid":false,"given":"Richard","family":"Buka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences University of Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-8788","authenticated-orcid":false,"given":"Rosalind","family":"Byrne","sequence":"additional","affiliation":[{"name":"Haematology, King's Thrombosis Centre King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-9522","authenticated-orcid":false,"given":"Stephen","family":"Black","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-9576","authenticated-orcid":false,"given":"Helen J.","family":"Curtis","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5184-0606","authenticated-orcid":false,"given":"Christopher","family":"Wood","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3688-8393","authenticated-orcid":false,"given":"Andrew","family":"Brown","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-3454","authenticated-orcid":false,"given":"Sebastian","family":"Bacon","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-9186","authenticated-orcid":false,"given":"Richard","family":"Croker","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-4728","authenticated-orcid":false,"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-9063","authenticated-orcid":false,"given":"Brian","family":"MacKenna","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-9375","authenticated-orcid":false,"given":"Victoria","family":"Speed","sequence":"additional","affiliation":[{"name":"Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences University of Oxford  Oxford UK"},{"name":"Haematology, King's Thrombosis Centre King's College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Overview | Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban [Internet]. NICE;2024.https:\/\/www.nice.org.uk\/guidance\/ta697"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814051"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313040"},{"key":"e_1_2_9_5_1","unstructured":"Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) [Internet]. NICE;2025.https:\/\/www.nice.org.uk\/guidance\/ta1029"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","unstructured":"British National Formulary [Internet].2024.Andexanet alfa medicinal forms.https:\/\/bnf.nice.org.uk\/drugs\/andexanet-alfa\/medicinal-forms\/","DOI":"10.1007\/s40278-024-66024-2"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.648"},{"key":"e_1_2_9_8_1","unstructured":"Open Data Portal (NHS Business Services Authority) [Internet].Secondary care medicines data (SCMD) with indicative price.https:\/\/opendata.nhsbsa.net\/dataset\/secondary-care-medicines-data-indicative-price"},{"key":"e_1_2_9_9_1","doi-asserted-by":"crossref","unstructured":"FisherL WoodC BrownA et al.OpenPrescribing hospitals: an open access analytics platform for hospital medicines use in England.doi:10.1101\/2025.11.13.25340060","DOI":"10.1101\/2025.11.13.25340060"},{"key":"e_1_2_9_10_1","unstructured":"OpenPrescribing Hospitals [Internet].2025.OpenPrescribing Hospitals.https:\/\/hospitals.openprescribing.net\/"},{"key":"e_1_2_9_11_1","unstructured":"OpenPrescribing Hospitals [Internet].2025.Analysis of andexanet alfa issuing using OpenPrescribing Hospitals.https:\/\/hospitals.openprescribing.net\/analyse\/?vmps=37454211000001101&quantity=dose"},{"key":"e_1_2_9_12_1","unstructured":"NHS Business Services Authority.NHS dictionary of medicines and devices (dm + d).https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/dictionary-medicines-and-devices-dmd"},{"key":"e_1_2_9_13_1","unstructured":"NHS Digital [Internet].NHS organisation data service.https:\/\/digital.nhs.uk\/services\/organisation-data-service"},{"key":"e_1_2_9_14_1","unstructured":"NHS England [Internet].2024.A&E attendances and emergency admissions.https:\/\/www.england.nhs.uk\/statistics\/statistical-work-areas\/ae-waiting-times-and-activity\/"},{"key":"e_1_2_9_15_1","unstructured":"OpenPrescribing [Internet].2025.OpenPrescribing.https:\/\/openprescribing.net\/"},{"key":"e_1_2_9_16_1","unstructured":"OpenPrescribing Hospitals [Internet].2025.Analysis of apixaban and rivaroxaban issuing using OpenPrescribing Hospitals.https:\/\/hospitals.openprescribing.net\/analyse\/?vtms=774624002 777455008&quantity=ddd"},{"key":"e_1_2_9_17_1","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology [Internet].2025.ATC\/DDD Index.https:\/\/atcddd.fhi.no\/atc_ddd_index\/"},{"key":"e_1_2_9_18_1","unstructured":"Electronic Medicines Compendium [Internet].2024.Ondexxya 200 mg powder for solution for infusion\u2014summary of product characteristics (SmPC).https:\/\/www.medicines.org.uk\/emc\/product\/10933\/smpc#:~:text=Andexanet%20alfa%20is%20a%20specific%20reversal"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15539"},{"key":"e_1_2_9_20_1","unstructured":"RCEM [Internet].2021.RCEM NPIS antidote guideline update 2021. Cited 2024 Sep 9.https:\/\/web.archive.org\/web\/20230615225238\/https:\/\/res.cloudinary.com\/studio-republic\/images\/v1636632437\/RCEM_NPIS_Antidote_Letter_Nov_2021-1\/RCEM_NPIS_Antidote_Letter_Nov_2021-1.pdf?_i=AA"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:48:06Z","timestamp":1779781686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/bcp.70417"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70417","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}